Randi has served as Werewolf Therapeutics’ Chief Medical Officer since November 2020. She speaks regularly about Werewolf and advanced immuno-oncology technologies to investors and other audiences. From May 2010 until November 2020, Randi held roles of increasing responsibility as Clinical Program Leader, Deputy Site Head, Site Head, and Interim Head of Translational Clinical Oncology at the Novartis Institutes for Biomedical Research. She previously held executive leadership roles in oncology and clinical development at Merck, Schering Plough, and Sandoz. Prior to transitioning to the biopharmaceutical industry, Randi held various academic appointments, including Assistant Professor of Medicine in the Division of Hematology/Oncology at the State University of New York Health Sciences Center and Clinical Assistant Professor of Hematology/Oncology at the University of Medicine and Dentistry of New Jersey. Randi previously served on the clinical advisory boards of C4 Therapeutics, Inc. and HOOKIPA Pharma. Randi also serves on the Scientific Advisory Boards of both the MMF Investment Fund and IFLI Innovation Advisory Board, both not-for-profit entities, and until recently Tiga Tx, Inc. a privately held entity. Randi holds an MD with honors from Dartmouth Medical School. She completed her residency and postdoctoral training at the University of California San Francisco and University of Pennsylvania and hematology/medical oncology fellowship training at the Memorial Sloan-Kettering Cancer Center.